The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1499-1501.e2. doi: 10.1016/j.cgh.2020.08.017.Epub 2020 Aug 12.
Donghee Kim1, George Cholankeril2, Rohit Loomba3, Aijaz Ahmed2
Author information
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. Electronic address: messmd@chol.com.
2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
3Nonalcoholic Fatty Liver Disease Research Center, University of California at San Diego, La Jolla, California; Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California.
Abstract
Fatty liver disease is a clinicopathologic spectrum that encompasses simple steatosis, steatohepatitis, advanced fibrosis, and cirrhosis. Transient elastography has evolved as an accurate technique and noninvasive tool for assessing hepatic fibrosis in clinical practice.1 The controlled attenuation parameter (CAP) score has been added to elastography, which computes ultrasound attenuation related to hepatic steatosis and improves the measurement of hepatic steatosis.1,2Given the unmet need to reckon the current burden of disease, it is essential to estimate the recent prevalence of fatty liver disease and fibrosis assessed by transient elastography in the United States. We investigated the sex-, race/ethnicity-, and body mass index-based prevalence of fatty liver disease and hepatic fibrosis by CAP-enhanced transient elastography in the United States.